glp-1 novo nordisk promotes new receptor agonist to fight diabetes, obesity < Pharma < Article Novo Nordisk, Eli Lilly cut
Description
This can be beneficial in the prevention and management of pre-diabetes and type 2 diabetes, where beta cell function is often impaired
On September 22, 2023, the FDA added a warning stating that semaglutide, the drug in Ozempic, has been reported to cause gastrointestinal disorders and bowel injuries
Addiction treatment potential: GLP-1 drugs affect brain reward pathways, decreasing reinforcement from alcohol and nicotine
In terms of patient type, chronic obesity segment to command 54.0% share in the glp-1 obesity home delivery injectables market in 2026
Pharmacology Biochemistry and Behavior
